BioSymetrics Signs an Agreement with Janssen and Sema4 to Utilize AI for the Prediction of COVID-19
Shots:
- The companies will use BioSymetrics Contingent-AI engine to characterize high-risk populations- measure and predict disease progression based on biological risk factors and treatment course and identify markers for clinical phenotype and severity of the disease
- The focus of the collaboration to predict the onset and severity of COVID-19 among different populations using machine learning
- The collaboration will operate across several projects with a goal of enabling a vaccine and course of treatment against COVID-19
Ref: PRNewswire | Image: Northeast Now
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com